Skip to main
KOD
KOD logo

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc. has demonstrated significant progress in its clinical pipeline, with four active Phase 3 trials for its lead assets, highlighting the company’s commitment to innovative treatments for retinal diseases. The company's R&D expenditures increased to $50.5 million, reflecting robust investment in clinical and manufacturing efforts, which is indicative of a strong development momentum. Recent data from the APEX study showing improvements in best-corrected visual acuity (BCVA) among patients reinforces the potential efficacy of its product candidates, particularly KSI-101 and tarcocimab, fostering a positive outlook for future clinical results and market reception.

Bears say

Kodiak Sciences Inc faces significant risks that contribute to an unfavorable outlook, including the potential failure of its product candidates to meet revenue projections due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may struggle to secure the necessary capital to fund its operations, especially as it seeks to establish a global sales and marketing infrastructure for its pipeline products, raising concerns about increasing cash burn. Lastly, the inconsistent efficacy of Tarcocimab and potential regulatory hurdles add further uncertainty to the developmental and commercialization prospects of its therapeutic candidates, jeopardizing future approval and financial performance.

KOD has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 6 analysts, KOD has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.